S3-Leitlinie Prostatakarzinom - AWMF

9. Literatur
334. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS,
Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton
CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A. Predicting the outcome of
salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin
Oncol 2007;25(15):2035-41. http://www.ncbi.nlm.nih.gov/pubmed/17513807
335. Pasquier D, Ballereau C. Adjuvant and salvage radiotherapy after prostatectomy for prostate
cancer: a literature review. Int J Radiat Oncol Biol Phys 2008;72(4):972-9.
http://www.ncbi.nlm.nih.gov/pubmed/18954710
336. Wiegel T, Lohm G, Bottke D, Hocht S, Miller K, Siegmann A, Schostak M, Neumann K,
Hinkelbein W. Achieving an undetectable PSA after radiotherapy for biochemical
progression after radical prostatectomy is an independent predictor of biochemical
outcome--results of a retrospective study. Int J Radiat Oncol Biol Phys 2009;73(4):1009-16.
http://www.ncbi.nlm.nih.gov/pubmed/18963539
337. Catton C, Gospodarowicz M, Warde P, Panzarella T, Catton P, McLean M, Milosevic M.
Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of
the prostate. Radiother Oncol 2001;59(1):51-60.
http://www.ncbi.nlm.nih.gov/pubmed/11295206
338. Coetzee LJ, Hars V, Paulson DF. Postoperative prostate-specific antigen as a prognostic
indicator in patients with margin-positive prostate cancer, undergoing adjuvant
radiotherapy after radical prostatectomy. Urology 1996;47(2):232-5.
http://www.ncbi.nlm.nih.gov/pubmed/8607240
339. Garg MK, Tekyi-Mensah S, Bolton S, Velasco J, Pontes E, Wood DP, Jr., Porter AT, Forman JD.
Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage
radiotherapy. Urology 1998;51(6):998-1002.
http://www.ncbi.nlm.nih.gov/pubmed/9609639
340. Morris MM, Dallow KC, Zietman AL, Park J, Althausen A, Heney NM, Shipley WU. Adjuvant
and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat
Oncol Biol Phys 1997;38(4):731-6. http://www.ncbi.nlm.nih.gov/pubmed/9240639
341. Zelefsky MJ, Aschkenasy E, Kelsen S, Leibel SA. Tolerance and early outcome results of
postprostatectomy three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys
1997;39(2):327-33. http://www.ncbi.nlm.nih.gov/pubmed/9308935
342. Heidenreich A, Richter S, Thuer D, Pfister D. Prognostic parameters, complications, and
oncologic and functional outcome of salvage radical prostatectomy for locally recurrent
prostate cancer after 21st-century radiotherapy. Eur Urol 2010;57(3):437-43.
http://www.ncbi.nlm.nih.gov/pubmed/19303197
343. Murat FJ, Poissonnier L, Rabilloud M, Belot A, Bouvier R, Rouviere O, Chapelon JY, Gelet A.
Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an
effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate
cancer. Eur Urol 2009;55(3):640-7. http://www.ncbi.nlm.nih.gov/pubmed/18508188
344. Berge V, Baco E, Karlsen SJ. A prospective study of salvage high-intensity focused
ultrasound for locally radiorecurrent prostate cancer: early results. Scand J Urol Nephrol
2010;44(4):223-7. http://www.ncbi.nlm.nih.gov/pubmed/20350272
345. Zacharakis E, Ahmed HU, Ishaq A, Scott R, Illing R, Freeman A, Allen C, Emberton M. The
feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent
prostate cancer following external beam radiotherapy. BJU Int 2008;102(7):786-92.
http://www.ncbi.nlm.nih.gov/pubmed/18564135
346. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp
SA, Smith TJ, Talcott J, Taplin M, Vogelzang NJ, Wade JL, III, Bennett CL, Scher HI. Initial
hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate
© Leitlinienprogramm Onkologie | S3-Leitlinie Prostatakarzinom | Version 2.0, 1. Aktualisierung 2011